Patents Assigned to MedImmune Limited
-
Publication number: 20120264919Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: April 23, 2012Publication date: October 18, 2012Applicants: MEDIMMUNE LIMITED, WYETH LLCInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, David LOWE, Viia VALGE-ARCHER
-
Patent number: 8288123Abstract: A method of providing a subject polypeptide variant with improved stability compared with a parent subject polypeptide, employing translation and selection using an RNA expression system, wherein two or more stability selection pressures are applied simultaneously during translation, two or more stability selection pressures are applied simultaneously during selecting, or at least one stability selection pressure is applied during translation and continues to be applied during selecting, and at least one further stability selection pressure is applied during selecting.Type: GrantFiled: January 5, 2006Date of Patent: October 16, 2012Assignee: MedImmune LimitedInventors: Andrew Buchanan, Lutz Jermutus
-
Publication number: 20120258090Abstract: The present invention relates to a method is provided for producing recombinant human thrombin from recombinant prothrombin using recombinant ecarin having the sequence SEQ ID NO 2 or a homologue thereof.Type: ApplicationFiled: June 15, 2012Publication date: October 11, 2012Applicant: MedImmune LimitedInventors: Anna Harrysson, Ann Lövgren
-
Patent number: 8263075Abstract: Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis is also provided.Type: GrantFiled: March 27, 2007Date of Patent: September 11, 2012Assignee: MedImmune LimitedInventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Publication number: 20120171197Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: December 6, 2011Publication date: July 5, 2012Applicant: MEDIMMUNE LIMITEDInventors: PER-OLOF FREDRIK ERIKSSON, KARIN VON WACHENFELDT, SUZANNE COHEN, CLAIRE LOUISE DOBSON, DEBORAH LOUISE LANE
-
Patent number: 8206967Abstract: The present invention relates to compositions and methods for producing recombinant human thrombin using recombinant ecarin.Type: GrantFiled: July 3, 2008Date of Patent: June 26, 2012Assignee: MedImmune LimitedInventors: Anna Harrysson, Ann Lövgren
-
Patent number: 8198414Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumors associated with IL-6.Type: GrantFiled: November 30, 2007Date of Patent: June 12, 2012Assignee: MedImmune LimitedInventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
-
Patent number: 8187603Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 29, 2009Date of Patent: May 29, 2012Assignees: Wyeth LLC, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Publication number: 20120129710Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: ApplicationFiled: June 21, 2011Publication date: May 24, 2012Applicants: MEDIMMUNE LIMITED, MEDICAL RESEARCH COUNCILInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Hendricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kasper Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert
-
Patent number: 8182811Abstract: The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including arthritic disorders such as rheumatoid arthritis.Type: GrantFiled: December 4, 2009Date of Patent: May 22, 2012Assignee: MedImmune LimitedInventors: Wendy Barker, Feenagh Anne Keyes
-
Patent number: 8182817Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: January 29, 2010Date of Patent: May 22, 2012Assignees: Wyeth LLC, Medimmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
-
Publication number: 20120114667Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.Type: ApplicationFiled: December 21, 2009Publication date: May 10, 2012Applicant: MEDIMMUNE LIMITEDInventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry
-
Publication number: 20120108797Abstract: Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determine regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: ApplicationFiled: July 28, 2011Publication date: May 3, 2012Applicant: MedImmune LimitedInventors: Paul Elvin, Stephen Charles Emery, Qing Zhou
-
Patent number: 8163884Abstract: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 26, 2009Date of Patent: April 24, 2012Assignees: Wyeth LLC, MedImmune LimitedInventors: Laird Bloom, Davinder Gill, Yulia Vugmeyster, Deborah A. Young, David Lowe, Viia Valge-Archer
-
Patent number: 8153128Abstract: Binding members, especially antibody molecules that bind the IL-6:IL-6Ra complex formed by IL-6 and IL-6Ra, and do not bind either IL-6 or IL-6Ra alone. The binding members may have greater specificity for inhibiting pathological effects of IL-6 rather than beneficial effects of IL-6, as compared with binding members that bind IL-6 or IL-6Ra outside the IL-6:IL-6Ra complex.Type: GrantFiled: November 28, 2007Date of Patent: April 10, 2012Assignee: MedImmune LimitedInventors: Keith Bowers, Steven Godfrey Lane, Philip Mallinder, Isabelle Veronique Yolande Ossona De Mendez
-
Publication number: 20120052060Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: ApplicationFiled: November 8, 2010Publication date: March 1, 2012Applicant: MedImmune LimitedInventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
-
Patent number: 8119130Abstract: The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.Type: GrantFiled: July 23, 2008Date of Patent: February 21, 2012Assignee: MedImmune LimitedInventors: Simon Thomas Barry, Vahe Bedian, Bradley Hedberg, Jaspal Singh Kang, Qing Zhou
-
Patent number: 8092804Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: GrantFiled: December 18, 2008Date of Patent: January 10, 2012Assignee: MedImmune LimitedInventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Patent number: 8088736Abstract: Protein variants of CTLA-4, which show increased activity compared to wild-type in a cell assay and which exhibit increased stability. Such variants are useful for treatment of disorders whereby attenuation of the T cell response would be beneficial.Type: GrantFiled: October 22, 2007Date of Patent: January 3, 2012Assignee: MedImmune LimitedInventors: Ruth Franks, Mark Terence Liddament, Lutz Ulrich Jochen Wilhelm Jermutus, Andrew Grier Buchanan
-
Patent number: 8088905Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: March 16, 2009Date of Patent: January 3, 2012Assignees: Wyeth, MedImmune LimitedInventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell